CN101222923A - 可溶性鸟苷酸环化酶活化剂和刺激剂用于预防或治疗肾脏疾病的新用途 - Google Patents
可溶性鸟苷酸环化酶活化剂和刺激剂用于预防或治疗肾脏疾病的新用途 Download PDFInfo
- Publication number
- CN101222923A CN101222923A CNA2006800260905A CN200680026090A CN101222923A CN 101222923 A CN101222923 A CN 101222923A CN A2006800260905 A CNA2006800260905 A CN A2006800260905A CN 200680026090 A CN200680026090 A CN 200680026090A CN 101222923 A CN101222923 A CN 101222923A
- Authority
- CN
- China
- Prior art keywords
- renal failure
- treatment
- renal
- sgc
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
(IV) | 式(IV)所述化合物,其作为药物活性剂的生产和用途被公开于WO01/19780。 |
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05015522 | 2005-07-18 | ||
EP05015522.5 | 2005-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101222923A true CN101222923A (zh) | 2008-07-16 |
Family
ID=37075729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800260905A Pending CN101222923A (zh) | 2005-07-18 | 2006-07-06 | 可溶性鸟苷酸环化酶活化剂和刺激剂用于预防或治疗肾脏疾病的新用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20100016305A1 (zh) |
EP (1) | EP1906957A1 (zh) |
JP (1) | JP2009501739A (zh) |
KR (1) | KR20080030669A (zh) |
CN (1) | CN101222923A (zh) |
AU (1) | AU2006272088A1 (zh) |
BR (1) | BRPI0614001A2 (zh) |
CA (1) | CA2615426A1 (zh) |
IL (1) | IL188657A0 (zh) |
MX (1) | MX2008000779A (zh) |
RU (1) | RU2008105481A (zh) |
WO (1) | WO2007009607A1 (zh) |
ZA (1) | ZA200800466B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104434845A (zh) * | 2014-11-12 | 2015-03-25 | 广东东阳光药业有限公司 | 一种包含利奥西呱的固体药物制剂 |
CN105979959A (zh) * | 2013-08-09 | 2016-09-28 | 阿德利克斯公司 | 用于抑制磷酸盐转运的化合物和方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007015034A1 (de) * | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2011056511A2 (en) | 2009-10-26 | 2011-05-12 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
DE102009046115A1 (de) * | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
RS54261B1 (en) * | 2010-05-26 | 2016-02-29 | Adverio Pharma Gmbh | USE OF SGC STIMULATORS, SGC ACTIVATORS, INDIVIDUALLY AND IN COMBINATION WITH PDE5 INHIBITORS FOR SYSTEMIC SCLEROSIS TREATMENT (SSC) |
EA023254B1 (ru) | 2010-05-27 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
EP2585055A1 (de) * | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
US8815857B2 (en) | 2011-08-12 | 2014-08-26 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
CN104619695B (zh) | 2012-09-07 | 2018-04-10 | 勃林格殷格翰国际有限公司 | 作为可溶性鸟苷酸环化酶活化剂的烷氧吡唑 |
EP4223339A1 (en) * | 2013-03-14 | 2023-08-09 | Fisher & Paykel Healthcare Limited | Catheter mount with suction port |
EP4052675A1 (en) * | 2014-03-17 | 2022-09-07 | Intuitive Surgical Operations, Inc. | Latch to secure teleoperated surgical instrument to actuator |
AP2016009615A0 (en) | 2014-07-22 | 2016-12-31 | Boehringer Ingelheim Int | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1095016B1 (en) * | 1998-07-08 | 2005-11-09 | Sanofi-Aventis Deutschland GmbH | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943635A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10351903A1 (de) * | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
DE102004012365A1 (de) * | 2004-03-13 | 2005-09-29 | Bayer Healthcare Ag | Substituierte Dihydropyridine |
-
2006
- 2006-07-06 MX MX2008000779A patent/MX2008000779A/es unknown
- 2006-07-06 JP JP2008521837A patent/JP2009501739A/ja active Pending
- 2006-07-06 US US11/989,068 patent/US20100016305A1/en not_active Abandoned
- 2006-07-06 KR KR1020087003678A patent/KR20080030669A/ko not_active Application Discontinuation
- 2006-07-06 WO PCT/EP2006/006601 patent/WO2007009607A1/en active Application Filing
- 2006-07-06 AU AU2006272088A patent/AU2006272088A1/en not_active Abandoned
- 2006-07-06 CN CNA2006800260905A patent/CN101222923A/zh active Pending
- 2006-07-06 RU RU2008105481/15A patent/RU2008105481A/ru not_active Application Discontinuation
- 2006-07-06 BR BRPI0614001-7A patent/BRPI0614001A2/pt not_active IP Right Cessation
- 2006-07-06 CA CA002615426A patent/CA2615426A1/en not_active Abandoned
- 2006-07-06 EP EP06762455A patent/EP1906957A1/en not_active Withdrawn
-
2008
- 2008-01-08 IL IL188657A patent/IL188657A0/en unknown
- 2008-01-16 ZA ZA200800466A patent/ZA200800466B/xx unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105979959A (zh) * | 2013-08-09 | 2016-09-28 | 阿德利克斯公司 | 用于抑制磷酸盐转运的化合物和方法 |
CN105979959B (zh) * | 2013-08-09 | 2021-11-30 | 阿德利克斯公司 | 用于抑制磷酸盐转运的化合物和方法 |
CN104434845A (zh) * | 2014-11-12 | 2015-03-25 | 广东东阳光药业有限公司 | 一种包含利奥西呱的固体药物制剂 |
CN104434845B (zh) * | 2014-11-12 | 2017-12-05 | 广东东阳光药业有限公司 | 一种包含利奥西呱的固体药物制剂 |
Also Published As
Publication number | Publication date |
---|---|
EP1906957A1 (en) | 2008-04-09 |
MX2008000779A (es) | 2008-02-21 |
AU2006272088A1 (en) | 2007-01-25 |
WO2007009607A1 (en) | 2007-01-25 |
BRPI0614001A2 (pt) | 2011-03-01 |
RU2008105481A (ru) | 2009-08-27 |
IL188657A0 (en) | 2008-12-29 |
ZA200800466B (en) | 2009-05-27 |
KR20080030669A (ko) | 2008-04-04 |
JP2009501739A (ja) | 2009-01-22 |
CA2615426A1 (en) | 2007-01-25 |
US20100016305A1 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101222923A (zh) | 可溶性鸟苷酸环化酶活化剂和刺激剂用于预防或治疗肾脏疾病的新用途 | |
ES2311117T3 (es) | Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa. | |
ES2301142T3 (es) | Combinaciones que comprenden inhibidores de dipeptidilpeptidasa-iv y agentes antidiabeticos. | |
Kelton et al. | A rapid method for the diagnosis of acute uric acid nephropathy | |
Iseri et al. | Magnesium deficiency and cardiac disorders | |
Vasavada et al. | A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease | |
US20050070607A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions | |
TW201040193A (en) | Pharmaceutical composition, methods for treating and uses thereof | |
Llanos-Cuentas et al. | Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis | |
BR112021006002A2 (pt) | composições para a redução de ácido úrico sérico | |
Bryan | Nitric oxide deficiency is a primary driver of hypertension | |
Umeki et al. | Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity | |
Bendz et al. | Kidney function in an unselected lithium population: A cross‐sectional study | |
Lee et al. | Outcome of patients with lithium poisoning at a far-east poison center | |
Jackson et al. | Iatrogenic magnesium overdose: 2 case reports | |
AU2018283781B2 (en) | Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus | |
Preston et al. | Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus | |
Lin et al. | Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standard doses of trimethoprim-sulphamethoxazole. | |
Costello et al. | Effect of vitamin B6 supplementation on plasma oxalate and oxalate removal rate in hemodialysis patients. | |
Nakamura et al. | Diuretic effects of a novel uricosuric antihypertensive S‐8666 in rats, mice, monkeys, and dogs: Comparison with furosemide and trichlormethiazide | |
US6355682B1 (en) | Treatment of acute renal failure by administration of N-acetylcysteine | |
CH675684A5 (zh) | ||
US20210145783A1 (en) | Compositions and Methods for Treating Sickle Cell Disease | |
RU2192870C1 (ru) | Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией | |
TWI798578B (zh) | 棘白菌素類化合物於治療黃病毒感染症的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Denomination of Invention Correct: Novel use of soluble guanylate cyclase activating agents and stimulants for the prevention or treatment of kidney diseases False: Novel use of soluble guanylate cyclase activating agents and stimulants for the prevention or treatment of kidney disorders Number: 29 Page: 972 Volume: 24 |
|
CI02 | Correction of invention patent application |
Correction item: Denomination of Invention Correct: Novel use of soluble guanylate cyclase activating agents and stimulants for the prevention or treatment of kidney diseases False: Novel use of soluble guanylate cyclase activating agents and stimulants for the prevention or treatment of kidney disorders Number: 29 Page: The title page Volume: 24 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTION NAME; FROM: NEW USE OF SOLUBLE GUANYLATE CYCLASE ACTIVATOR AND STIMULATING AGENTFOR THE PREVENTION OR TREATMENT OF KIDNEY PROBLEMS TO: NEW USE OF SOLUBLE GUANYLATE CYCLASE ACTIVATOR AND STIMULATING AGENT FOR THE PREVENTION OR TREATMENT OF KIDNEY DISEASES |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTION NAME; FROM: NEW USE OF SOLUBLE GUANYLATE CYCLASE ACTIVATOR AND STIMULATING AGENTFOR THE PREVENTION OR TREATMENT OF KIDNEY PROBLEMS TO: NEW USE OF SOLUBLE GUANYLATE CYCLASE ACTIVATOR AND STIMULATING AGENT FOR THE PREVENTION OR TREATMENT OF KIDNEY DISEASES |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1122990 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BAYER SCHERING PHARMA AG Free format text: FORMER OWNER: BAYER HEALTHCARE AG Effective date: 20091127 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091127 Address after: Berlin Applicant after: Bayer Schering Pharma AG Address before: Germany Leverkusen Applicant before: Bayer Healthcare AG |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20080716 |